Compounded bioidentical hormone therapy sits at the intersection of individualized medicine and careful risk management. The promise is appealing, a formula tailored to your symptoms, your physiology, and your preferences for route and base. The challenge is equally clear, quality can vary, evidence for certain claims is uneven, and dosing requires a steady hand. After years of working with hormone therapy and cleaning up problems that started with good intentions, I have learned where compounded bioidentical hormones shine and where they demand extra scrutiny.
What “bioidentical” really means
Bioidentical refers to the molecule itself, not the source or the marketing. Estradiol, progesterone, and testosterone that match the structure made by human ovaries or testes are bioidentical, whether they originate from yams or soy precursors and are synthesized to final form. So an FDA approved estradiol patch is bioidentical. A compounded estradiol cream is also bioidentical. Conjugated equine estrogens, medroxyprogesterone acetate, and many oral synthetics are not bioidentical because their structure differs from human hormones.
This matters for pharmacology. Oral micronized progesterone has sedative metabolites that often improve sleep. Transdermal estradiol avoids first pass hepatic effects that raise clotting factors. Testosterone undecanoate taken orally relies on lymphatic absorption and behaves differently than injected cypionate. The molecule and the route both shape risk and benefit.
When compounding is reasonable
Compounded therapy has an appropriate role. Not every patient fits the standard box, and FDA approved hormone replacement therapy options are robust but not limitless. I consider compounding when a patient:
- Needs a dose or combination that is not commercially available. For example, estradiol 0.25 mg per gram in a hypoallergenic vaginal base for severe vulvovaginal atrophy with pelvic floor dysfunction, or a low dose transdermal testosterone cream for a postmenopausal woman with distressing low libido after ruling out other causes. Cannot tolerate excipients in commercial products. I recall a math teacher with disabling hot flashes who broke out in hives from every adhesive patch and had migraines triggered by a common gel base. A compounding pharmacy prepared a simple estradiol-in-olive-oil topical that solved both problems. Requires an alternative route for a unique clinical reason. For instance, severe malabsorption after bariatric surgery can impair oral absorption, and compounding allows sublingual or transdermal dosing without propylene glycol. Needs vaginal dosing precision for genitourinary syndrome of menopause, lichen sclerosus, or pelvic radiation changes when off-the-shelf applicators are too coarse for comfort. Seeks testosterone therapy for women, which in many countries lacks approved female specific formulations. With shared decision making, a low dose compounded cream can be appropriate with careful monitoring.
Despite these niches, many patients do very well on FDA approved estradiol patches or gels, oral micronized progesterone, and established testosterone replacement therapy regimens for men. If you can meet the clinical goal with a verified, standardized product, it often reduces uncertainty.
The evidence and what it does, and does not, tell us
Bioidentical hormone therapy is not a monolith. We have strong evidence that transdermal estradiol paired with oral micronized progesterone can relieve vasomotor symptoms, improve sleep, and support bone density with a different risk profile than older oral synthetic regimens. Randomized trials and meta analyses have shown that oral estrogen raises VTE risk more than transdermal preparations. Micronized progesterone appears less adverse for lipids and possibly for breast tissue biology than some synthetic progestins.
The evidence for compounded bioidentical hormones is less robust for a simple reason, products vary between pharmacies, formulas change, and large randomized trials are scarce. The North American Menopause Society, the Endocrine Society, and other groups generally recommend FDA approved options first for hormone replacement therapy, and to reserve compounding for specific indications like intolerance or unavailability. This is not an indictment of compounding, it is a statement about verification and reproducibility. When something is customized, it is harder to study at scale.
Claims that compounded hormones are universally safer because they are “natural” or that saliva testing makes micro titration straightforward do not hold up under scrutiny. Salivary hormones vary with flow rate, time of day, and binding proteins. Clinical endpoints and blood levels, not saliva alone, guide responsible dosing.
Dosing principles that hold up in real practice
Good hormone balancing respects three truths. First, symptoms are real but subjective. Second, blood levels offer reference points but are not the whole story. Third, the route changes everything.
" width="560" height="315" style="border: none;" allowfullscreen="" >
Start at the lower end of an effective range, reassess in 6 to 8 weeks, and adjust by the smallest increment that moves symptoms without overshooting physiologic windows. Educate patients about what to expect in week one, week two, and month two. Many stop too early or push too hard because no one set expectations.
Typical ranges I use, recognizing that individual needs vary:
- Estradiol for menopausal vasomotor symptoms. Transdermal patches are often 25 to 100 micrograms per day. Gels deliver 0.5 to 1.5 mg per day. Oral estradiol is usually 0.5 to 2 mg per day. I prefer transdermal in patients with migraine, hypertension, obesity, or elevated VTE risk. Vaginal estradiol for genitourinary syndrome is much lower, often 10 micrograms twice weekly after a brief loading phase. Progestogen for endometrial protection with systemic estrogen. Oral micronized progesterone 100 mg nightly for continuous therapy, or 200 mg nightly for 12 to 14 days per month for cyclic therapy. In my practice, compounded transdermal progesterone creams do not reliably protect the endometrium despite normal serum readings. If a patient insists on transdermal progesterone, I increase endometrial surveillance with ultrasound and low threshold biopsy if bleeding occurs. Testosterone for men with confirmed hypogonadism. Gels provide 50 to 100 mg daily, typically titrated to achieve mid normal morning total testosterone and symptom relief without driving hematocrit above about 52 percent. Injectables vary, cypionate or enanthate 75 to 100 mg weekly or 150 to 200 mg every 2 weeks are common, though weekly or twice weekly prevents peaks and troughs. Compounded creams in men can work but absorbability is base dependent and highly variable. Testosterone for women with hypoactive sexual desire disorder after evaluation. Compounded transdermal dosing often starts around 0.5 to 1 mg daily, titrated to a female appropriate reference range for total and free testosterone. Watch for acne, hair growth, voice changes, and mood shifts. This is off label in many regions and requires informed consent. DHEA. I am cautious. Oral DHEA 5 to 25 mg can help some with fatigue or low libido, but conversion pathways are not predictable, especially in women. Vaginal DHEA 6.5 mg is FDA approved for dyspareunia and often works well with minimal systemic effects. Thyroid hormone therapy should not be casually compounded unless there is a clear need, such as a dye allergy. T4 and T3 content must be exact. Many patients do best on stable, FDA approved levothyroxine with weight based dosing and careful timing.
Steady state for transdermal and oral estradiol is generally achieved in 3 to 5 days, but symptom stabilization often takes weeks as receptors reset. For testosterone injections, steady state arrives after several half lives, roughly 2 to 5 weeks depending on frequency. Do not chase weekly noise.
Route and risk are linked
If you remember one pharmacology rule for hormone treatment, let it be this. Oral estrogen goes through the liver and upregulates clotting proteins, binding globulins, and triglycerides. Transdermal estrogen largely avoids that first pass and has a different cardiovascular and thrombotic profile. In women with prior VTE, significant obesity, or migraine with aura, transdermal is the safer route if systemic estrogen is used at all, in concert with their specialist.
Progesterone by mouth has sedative metabolites that help sleep. It can also cause morning grogginess in sensitive patients. Taking it with a small snack and allowing 8 hours of sleep time helps. Vaginal progesterone is effective in fertility care, but for endometrial protection in menopausal hormone replacement therapy, dosing and distribution remain inconsistent, and I use it selectively.
Testosterone has its own route quirks. Gels risk transference to a partner or child if not covered or washed off. Pellets provide long duration but not easy reversibility if side effects occur. Injections require attention to needle hygiene and dosing frequency to smooth peaks. For male hormone therapy, I check hematocrit at baseline, 3 months, 6 months, then at least annually. Erythrocytosis can sneak up and bring headaches, flushing, and a thick blood picture on labs.
Monitoring that prevents problems
I use a blend of symptom tracking and labs. For menopausal hormone therapy, I document baseline hot flash frequency, sleep quality, sexual comfort, and mood, then reassess at 6 to 8 weeks. If bleeding occurs after 6 months on continuous combined therapy, I evaluate. Even in the era of ultrasound and biomarkers, a simple, careful history remains the best early warning system.
On labs, I am pragmatic. For estradiol therapy, especially transdermal, numeric targets are less important than clinical response and safety. I do check estradiol and progesterone under certain circumstances, for example when absorption is in doubt or bleeding patterns are atypical. Thyroid function needs consistent timing relative to dosing. For testosterone therapy in men, I check total testosterone, sex hormone binding globulin, calculated free testosterone, hematocrit, lipid panel, and liver enzymes. PSA and prostate exam are individualized by age and risk, and I collaborate with a urologist when questions arise.
For women using low dose testosterone, I review total and free testosterone at baseline and 8 to 12 weeks after starting, then every 6 to 12 months. I also listen carefully for early androgenic side effects. For anyone on oral estrogen, I keep an eye on triglycerides. For high risk patients, I coordinate with hematology or cardiology.
Quality matters more with compounding
Compounded bioidentical hormones depend on the skills and systems of a specific pharmacy. I have seen estradiol creams that tested at 65 percent of labeled strength and pellets measured post removal that released far more than intended. Most compounding pharmacists take their craft seriously, but verification separates the best from the rest.
Look for a 503A pharmacy that follows USP chapters 795, 797, and when applicable 800. PCAB accreditation is a positive signal. I ask for certificates of analysis on bulk active ingredients and, for complex or high risk compounds, whether the pharmacy conducts potency or sterility testing by an independent lab. Consistency of the base is not trivial. Hormone absorption varies widely between PLO gel, Lipoderm, Versabase, and oil in wax. A dose that works in one base might underperform in another.
Ask about beyond use dates and storage. An estrogen cream kept in a hot car degrades faster. For injectables, I want to know the carrier oil, benzyl alcohol content, and particulate control. For pellets, I discuss hormone therapy the source of raw testosterone or estradiol, manufacturing controls, and how often the pharmacy assays finished pellets. A good pharmacy welcomes these questions.
Pellets, injections, and the temptation of convenience
Pellet hormone therapy has a devoted following. Insert a small cylinder of hormone under the skin and enjoy months of steady release. In reality, release rates vary by tissue perfusion, exercise, and pellet composition. I see more supraphysiologic testosterone levels from pellets than from other routes, and if a man develops erythrocytosis or a woman experiences virilizing side effects, the dose cannot be dialed down. You wait it out. That trade off may be acceptable for some after a candid discussion, but it should be a choice made with eyes open.
Injections are predictable and inexpensive. They do require more patient involvement and can swing levels if given every 2 weeks rather than weekly. Compounded creams appeal to those who dislike needles or adhesives, but I always confirm absorption objectively. A 100 mg per gram testosterone cream that delivers 10 mg on paper may deliver 4 to 8 mg through skin, depending on base and application site.
Myths that deserve retirement
Saliva testing for dosing titration is popular marketing. It is not a reliable compass for most patients on systemic hormone therapy. Intraindividual variability, carrier protein effects, and diurnal swings can overwhelm the small differences we try to measure. I treat using symptoms and blood levels where appropriate.
Compounded progesterone cream for endometrial protection sounds elegant, the lived experience is uneven. There are documented cases of proliferative endometrium and hyperplasia despite apparently normal blood levels. If systemic estrogen is used in a woman with a uterus, oral micronized progesterone at proven doses offers far more confidence.
Natural does not mean risk free. Estradiol does not know whether it came from a yam. A clot is a clot. The heart and breast do not read the label on the jar.
Special scenarios that reshape the plan
Migraine with aura leans me away from oral estrogen. I use the lowest effective transdermal dose and watch blood pressure. A history of VTE leads to a frank conversation with a hematologist before starting any systemic estrogen. Obstructive sleep apnea raises the risk of erythrocytosis with testosterone therapy, so I make sure it is identified and treated.
Gender affirming hormone therapy has its own frameworks and targets. For transfeminine patients, estradiol dosing and antiandrogen strategies follow evidence based protocols, with a strong bias toward transdermal routes for those over 45 or with cardiovascular risk. For transmasculine patients, testosterone therapy uses the same molecules as cis male therapy but with different goals and different attention to menstrual suppression, atrophy management, and fertility planning. Compounded options can help with dosing flexibility or excipient sensitivities, but the standards and labs are specific to gender affirming care.
Thyroid and adrenal hormones belong to a different lane. Compounded desiccated thyroid or custom T3 heavy blends can destabilize patients. Hydrocortisone for so called adrenal fatigue is not appropriate and can suppress the axis. I reserve cortisol treatment for true adrenal insufficiency diagnosed by proper testing.
A short, practical checklist for safer compounded hormone therapy
- Confirm the indication with a clear diagnosis, and rule out nonhormonal drivers of symptoms like iron deficiency, sleep apnea, medication side effects, or thyroid disease. Choose the simplest route and lowest dose likely to work, and adjust no faster than every 6 to 8 weeks unless side effects force a change sooner. Source from a pharmacy that is PCAB accredited or at minimum compliant with USP standards, and ask about potency testing of the final product. Pair systemic estrogen with proven endometrial protection if the uterus is present, and investigate any unexpected bleeding. Set a monitoring calendar in writing, including symptom review and specific labs tied to the therapy, and decide in advance what would trigger a dose reduction or pause.
Compounded versus FDA approved: a concise comparison
- Personalization. Compounded hormone therapy offers fine tuning of dose, base, and combination. FDA approved options offer standardized strengths and rigorous manufacturing controls. Evidence base. FDA approved HRT regimens have stronger trial data for efficacy and safety. Compounded bioidentical hormones rely more on extrapolation and observational experience. Quality assurance. FDA products undergo batch testing and post market surveillance. Compounded products depend on the individual pharmacy’s processes and may vary more in potency. Cost and coverage. Compounded prescriptions are often cash pay and can cost 40 to 150 dollars per month. Many FDA approved products have insurance coverage or generics. Reversibility and control. Gels and patches can be stopped quickly. Pellets persist for months, which raises the stakes if side effects occur.
What patients ask most, and how I answer
How long will it take to feel better? Hot flashes often ease within 1 to 2 weeks on estrogen therapy, sleep improves within days on oral micronized progesterone, and sexual comfort from vaginal estrogen builds over 4 to 8 weeks. Energy and mood are more variable. For testosterone therapy in men, libido may rise within weeks, strength changes lag by months, and body composition shifts take disciplined time.
What level should we aim for? I aim for a therapeutic window, not a single number. For estradiol, enough to control symptoms without breast tenderness or bleeding. For men on testosterone, a mid normal morning total testosterone with free testosterone in range, hematocrit below about 52 percent, and a patient who feels steady rather than spiky. For women on low dose testosterone, levels within the upper physiologic female range, not the male range.
Is compounded better than synthetic hormone therapy? The better question is which molecule and route fit your biology and goals. Bioidentical estradiol and progesterone have attractive features, and many FDA approved versions already offer them. Compounding can be better for you if you need a custom base, dose, or combination. It is not inherently safer, and it requires more diligence in sourcing and monitoring.
Can I lose weight on hormone therapy? Hormone treatment is not a weight loss drug. For some, it reduces water retention and improves sleep, which helps metabolism. For others, appetite or fluid shifts blur the scale. I pair hormone optimization with nutrition, resistance training, and sleep hygiene to stabilize body composition.
Building a durable plan with your clinician
Work with a hormone specialist who will talk plainly about risks, including rare but serious events. Demand shared decision making. A good hormone doctor or hormone clinic does not sell pellets as a membership perk or push multi hormone stacks without a clear rationale. The right clinician will back up a step if side effects appear, will avoid polypharmacy, and will taper or stop therapy if the risk benefit balance changes.
When symptoms are complex, I sometimes run a broader panel at baseline, not to chase numbers but to find hidden friction. A fasting lipid panel, A1c, ferritin, TSH and free T4, vitamin D, B12, and morning cortisol in select cases. If we find iron deficiency, sleep apnea, or poorly controlled thyroid disease, the best hormone optimization is to fix those first.
The nuts and bolts of prescription writing also matter. Clear strength per mL or per gram, exact application site and frequency, refills aligned with follow up timing, and instructions that make sense in a sleepy bathroom at 6 a.m. I prefer metered dose pumps for creams and gels when available to reduce variance. For injections, I document needle size, site rotation, and disposal.
A note on expectations
I ask estrogen therapy New Providence patients to think in quarters, not weeks. By the end of quarter one, vasomotor symptoms should be quiet, sleep better, and side effects minimal. By the end of quarter two, exercise and nutrition habits layer in with the hormonal foundation. By the end of quarter three, we can judge whether the new normal feels sustainable. If it does not, we simplify the regimen rather than stacking more hormones.
I also discuss exit ramps. If breast cancer risk evolves, if a DVT occurs, if hematocrit climbs despite dose adjustments, or if acne and mood lability appear on testosterone, we have a plan to pause and reassess. Hormone restoration therapy is not a one way road.
The bottom line
Compounded bioidentical hormones can be a helpful tool in hormone imbalance treatment when you need flexibility that standard products cannot provide. They can also mislead if sold as a panacea. Safety lives in the details, the right molecule, the right route, a dosing plan that respects physiology, and a pharmacy that proves its quality. Whether you pursue menopause relief treatment with transdermal estradiol and oral micronized progesterone, low testosterone treatment with a steady injection schedule, or a carefully dosed female testosterone cream for low libido, insist on transparent reasoning and measurable guardrails.
If you approach hormone therapy as a partnership, balanced between lived symptoms and lab grounded checks, you can capture most of the benefits of hormone rebalancing while side stepping the common traps. That balance, not the buzzword on the label, is what restores energy, sleep, sexual comfort, and day to day steadiness.